PURPOSE: To determine the effect of IM 10milligram triamcinolone acetonide on the treatment outcomes of patients with mild to moderate persistent bronchial asthma using the Asthma Control Test (ACT).
METHODS: All patients studied were known bronchial asthmatics (diagnosed and classified according GINA 2008 guidelines) attending the chest clinic and on standard medication for Asthma control. Forced Expiratory Volume in 1s (FEV1), FVC. FEV1/FVC, PEF, PEF25, PEF50 and PEF75 were measured by standard methods. One group received single dose IM 10mg triamcinolone acetonide along with their existing standard medications and the second group did not receive triamcinolone acetonide along with standard medication. Asthma Control Test (using 5 standard questions with max of score of 5 per question). The total score recorded. Scores < 20 is off target, 20-24 on target 25 total control) was administered at the beginning, after 4th, 8th , 12th and 16th weeks on treatment. The results were compared using the SPSS version 13.0 software.
RESULTS: A total of 53 patients with 31(58.5%) in the triamcinolone acetonide group and 22(41.5%) in the non-triamcinolone group were studied. After 8 weeks on treatment, the ventillatory function parameters FEV1 (p=0.0032), FVC (p=0.0024), PEF (p=0.00120), PEF25 (p=0.0041), PEF50(p=0.0036) PEF75(p=0.0042) were significantly higher in the triamcinolone acetonide group. The Asthma control test scores were also significantly higher in the triamcinolone group at 4 weeks, 8 weeks and12 weeks respectively on treatment. ((p=0.0001), (p=0.0020) and (p=0.0021)) respectively.
CONCLUSION: Addition of a single dose IM 10mg triamcinolone acetonide to the current standard treatment regime for mild to moderate persistent asthma results in improved treatment outcomes.
CLINICAL IMPLICATIONS: Patients with mild to moderate persistent asthma may be offered a single dose of IM 10mg triamcinolone acetonide every 3 months to improve their clinical characteristics.Patient. This may be useful in the management of difficulty to treat/poor response to standard treatment regime bronchial asthma. Large multi-centered study/studies will be needed to validate the above findings.
DISCLOSURE: Kingsley Osagie, No Financial Disclosure Information; No Product/Research Disclosure Information